Citizens Initiates Coverage of Avalo Therapeutics (AVTX) with Market Outperform Recommendation

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks AVTX Citizens Initiates Coverage of Avalo Therapeutics (AVTX) with Market Outperform Recommendation April 06, 2026 — 08:04 pm EDT Written by George Maybach for Fintel-> Fintel reports that on April 6, 2026, Citizens initiated coverage of Avalo Therapeutics (NasdaqCM:AVTX) with a Market Outperform recommendation.

Analyst Price Forecast Suggests 108.03% Upside As of March 27, 2026, the average one-year price target for Avalo Therapeutics is $36.95/share. The forecasts range from a low of $24.24 to a high of $52.50. The average price target represents an increase of 108.03% from its latest reported closing price of $17.76 / share. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Avalo Therapeutics is 71MM, an increase of 120,018.64%. The projected annual non-GAAP EPS is -1.10. What is the Fund Sentiment? There are 87 funds or institutions reporting positions in Avalo Therapeutics. This is an increase of 11 owner(s) or 14.47% in the last quarter. Average portfolio weight of all funds dedicated to AVTX is 0.14%, an increase of 29.91%. Total shares owned by institutions increased in the last three months by 25.52% to 19,370K shares. The put/call ratio of AVTX is 0.32, indicating a bullish outlook. What are Other Shareholders Doing? Bvf holds 1,355K shares representing 5.95% ownership of the company. In its prior filing, the firm reported owning 1,355K shares , representing an increase of 0.00%. The firm increased its portfolio allocation in AVTX by 18.65% over the last quarter.

Nantahala Capital Management holds 1,235K shares representing 5.42% ownership of the company. No change in the last quarter. Orbimed Advisors holds 1,187K shares representing 5.21% ownership of the company. In its prior filing, the firm reported owning 1,349K shares , representing a decrease of 13.64%. The firm increased its portfolio allocation in AVTX by 9.12% over the last quarter.

Affinity Asset Advisors holds 1,051K shares representing 4.61% ownership of the company. In its prior filing, the firm reported owning 1,006K shares , representing an increase of 4.27%. Caligan Partners holds 882K shares representing 3.87% ownership of the company. In its prior filing, the firm reported owning 833K shares , representing an increase of 5.47%. The firm decreased its portfolio allocation in AVTX by 5.00% over the last quarter. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Click to Learn MoreThis story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags Stocks Fintel Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford. Check out our Unique Analysis of Insider Sentiment for Avalo Therapeutics, Inc.-> Find out what the Options Markets think of Avalo Therapeutics, Inc.-> See our take on Avalo Therapeutics, Inc. Upcoming Earnings-> More articles by this source-> Stocks mentioned AVTX More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.